Global Electronic Clinical Outcome Assessment (eCOA) Market is expected to grow with the CAGR of 15.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-electronic-clinical-outcome-assessment-ecoa-market

Global electronic clinical outcome assessment (eCOA) market is a fragmented market, which includes several key players as well as local players. The market has witnessed increased strategic developments and market expansion owing to favourable market scenario.

The major players dealing in global electronic clinical outcome assessment (eCOA) market are introducing easy to use product portfolio. This is helping companies to maximize the sales along with increased adoption among end users. For instance, in September, 2019, Oracle announced collaboration with Box. This collaboration will allow users to link their cloud and on-premises Oracle and third-party claims with Box via Oracle Integration. This seamless solution provided by the collaboration to the consumers, Oracle was benefitted in gaining credibility in the market which increased its market demand. This collaboration was proved to be beneficial for Oracle as it made its product more efficient rendering good result and reviews from the recipients.

Oracle is the dominating player in global electronic clinical outcome assessment (eCOA) market. The other key players existing in the market includes Parexel International Corporation, ERT Clinical, Bioclinica, IBM Corporation, eClinical Solutions LLC, ArisGlobal LLC, Signant Health, Medidata, Omnicomm Systems, Inc., YPrime, LLC, Clinical Ink, and WIRB-Copernicus Group.

Oracle

Oracle is headquartered in California, U.S. and was founded in 1977. The company offers solutions and services for holistic aspects of corporate information technology (IT) environments. This includes infrastructure, applications, and platforms as well. The offerings of Oracle include cloud and on-premise software, hardware and services. The company’s software business consists of three segments which include cloud services and license support, cloud license and on‐premise license, company offers product categories such as generation 2 cloud infrastructures, on premise infrastructure, cloud applications, industry applications, on premise applications.

• In February 2020, the company is highly focused towards market expansion. This is evident from the launch of the company’s cloud system in Australia (Melbourne), Japan (Osaka), Saudi Arabia (Jeddah), The Netherlands (Amsterdam) and Canada (Montreal)

The company has wide global presence across the globe including North America, Europe, Middle East & Africa, Asia-Pacific, and South America. In addition to it, the company also generates its revenue from the various subsidiary companies such as Acme Packet, BEA Systems, Hyperion Corporation, MICROS Systems, NetSuite, PeopleSoft, Siebel Systems, and Sun Microsystems among others.

Parexel International Corporation

Parexel International Corporation is headquartered in Massachusetts, U.S. and it was founded in year 1982. The company primarily caters to requirements of biopharmaceutical industry but largely focused towards global health. The company offers a suite of biopharmaceutical services that help companies to transform scientific discoveries into new treatments. The company’s services expand across clinical trials, regulatory compliance, market access, and consulting.  The product categories include clinical development, outsourcing services, integrated technologies, regulatory & access consulting, medical communications, medical and scientific services, real-world evidence and late phase, solutions by industry and solutions by development phase. However, the market focused categories are clinical development, integrated technologies, regulatory & access consulting, and real-world evidence and late phase.

• In December 2019, the company announced a new collaboration hub in the Cambridge Innovation Center (CIC); this collaboration is focused towards connecting with the innovation hub at Cambridge and Kendall Square for enhancement of product portfolio.

The company has presence in Asia-Pacific, Europe, Middle East & Africa, South America, North America with its various subsidiaries such as BVUD Research (India) Private Limited, HERON Health Pvt. Ltd, Mirai Placebo B.V., ClinPhone Development Ltd., Perceptive eClinical Limited,  ClinPhone Limited among others.

ERT Clinical

ERT Clinical is headquartered in Pennsylvania, U.S. was founded in 1972. The company is focused towards solutions for patient safety and high quality endpoint data collection solutions for clinical research and trials. The product and service portfolio of the company includes technology, clinical consulting and support services to enhance the the accuracy and reliability of data collection process. It includes electronic clinical outcome assessments (eCOA) along with patient, clinician, observer and performance reported outcomes. The company also offers cloud-based analytics and performance metrics.

• In March 2019, The company is also undertaking strategic decisions in order to streamline and improve operations. ERT Clinical announced that the company plans on moving its Japan-based offices to an increased facility in central Tokyo. The relocation of a commercial hub is expected to impact the company positively.

The company has wide global presence in North America, Europe, Middle East and Africa, South Americas, and Asia-Pacific. Few subsidiaries of the company include Biomedical Systems, Exco inTouch Ltd, ImageIQ, Inc, Biosigna GmbH, eRT Investment Corp, and eResearchTechnology GmbH amongst others.